Estrogen/Progesterone Receptor with Interpretation by Immunohistochemistry
Also known as: ERPR IP
Use
This test aids in the prediction of response to antiestrogen agents for patients with ductal carcinoma in situ (DCIS) and invasive cancers. It evaluates the presence of estrogen and progesterone receptors, which are critical for guiding treatment options in breast cancer therapy.
Special Instructions
Document time from tissue acquisition to fixation and fixation duration on submitting requisition or enter at time of order. Multiple specimens sent to ARUP must be accompanied by either an order comment directing pathologist selection of the specimen or individual orders for each sample.
Limitations
Specimens fixed for less than 6 hours or greater than 72 hours are unacceptable. Paraffin block with no tumor tissue remaining and specimens with fixation delayed for more than one hour will be rejected. Specimens must be fixed in 10 percent neutral buffered formalin; other fixatives are not acceptable.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 40556-3
- 14228-1
- 10480-2
- 14230-7
- 55229-9
- 94736-6
- 31208-2
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
4 slides
Container
Tissue block or 5 unstained, positively charged slides
Collection Instructions
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue no later than 1 hour after removal from patient. If sending precut slides, do not oven bake.
Storage Instructions
Room temperature or refrigerated. Ship in cooled container during summer months.
Causes for Rejection
Paraffin block with no tumor tissue remaining, fixation delayed over one hour, tissue fixed less than 6 hours or more than 72 hours, decalcified specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinitely |
| Refrigerated | Indefinitely |
| Frozen | Unacceptable |